Clinical trial · Interventional
Intravenous Lidocaine Plus Intratracheal Dexmedetomidine on Postoperative Sore Throat
Effect of Intravenous Lidocaine Combined With Intratracheal Dexmedetomidine on Postoperative Throat Pain in Patients Undergoing Thyroid Cancer Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objective: The present study was to investigate the effect of intravenous lidocaine combined with intratracheal dexmedetomidine on postoperative sore throat in patients undergoing thyroid cancer surgery. Methods: Investigators enrolled 144 patients with American Society of Anesthesiologists (ASA) physical status I and II, aged 18-65 years, and scheduled for elective undergoing thyroid cancer surgery with general anesthesia. The participants were randomly assigned into four groups(n=36 each group): Group L received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia. Group D received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL). Group LD received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL). Group C received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia.The incidence and severity of postoperative sore throat were recorded in four groups at 1 h, 2 h, 6 h, 24 h and 48 h after operation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dexmedetomidine | — | UNRESOLVED | — |
| Lidocaine | — | UNRESOLVED | — |
| Sore Throat | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Intracheal dexmedetomidine | Drug | — | UNRESOLVED |
| Intravenous lidocaine | Drug | — | UNRESOLVED |
| Intravenous lidocaine combined with intracheal dexmedetomidine | Drug | — | UNRESOLVED |
| Saline (NaCl 0,9 %) (placebo) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Intravenous lidocaine
- description
- Group L received lidocaine 1.5 mg/kg was injected intravenously 3 min before endotracheal intubation and tracheal spray with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
- interventionNames
- Drug: Intravenous lidocaine
- type
- EXPERIMENTAL
- label
- Intracheal dexmedetomidine
- description
- Group D received equal volume normal saline was injected intravenously 3 min before tracheal intubation and tracheal spray with dexmedetomidine (1 μg/kg) mixed with 0.8% ropivacaine 40 mg (5 mL) for surface anesthesia
- interventionNames
- Drug: Intracheal dexmedetomidine
- type
- EXPERIMENTAL
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Thyroid cancer surgery with ASA grades I-II * Aged 18-65 years * The patient's communication is normal and they have a certain learning ability Exclusion Criteria: * Severe respiratory and circulatory system diseases * There was bradycardia (HR \< 60 beats/minute) or atrioventricular block before the operation * Nervous system disease * Mental and psychological disorders * Abnormal liver and kidney functions * Pregnant and lactating women
References
Publications (0)
Data not yet available